| Prev Close | 54.70 |
| Open | 54.20 |
| Day Low/High | 53.75 / 55.10 |
| 52 Wk Low/High | 47.00 / 136.90 |
| Volume | 194.56K |
| Avg Volume | 681.20K |
| Exchange | NASDAQ |
| Shares Outstanding | 37.81M |
| Market Cap | 2.05B |
| EPS | -7.80 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2018.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pint Pharma International S.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that NERLYNX® (neratinib) has been included as a recommended treatment option in the latest National Comprehensive Cancer Network...
The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Puma Biotechnology, Inc.
Jim Cramer focuses on Home Depot, Vale, Bank of America, Kraft Heinz, Dominion Energy, Lululemon Athletica, StitchFix, Duke Energy and more.
Jim Cramer says that on Thursday we saw the right stocks rally, even if we didn't see it in the averages. This market had breadth.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2017.
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion, recommending the refusal of the...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, have entered into an...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that initial results from the company's ongoing SUMMIT Phase II 'basket' clinical trial of PB272 (neratinib) in patients with tumors harboring...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Medison Pharma Ltd, Israel's leading commercial partner for innovative pharmaceuticals, have entered into an exclusive agreement under which Medison...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced that on January 16, 2018 the Compensation Committee of Puma's Board of Directors approved the grant of an inducement stock option to...
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has communicated a negative trend vote after meeting with the Company...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) as part of the NBI's annual re-ranking of biotechnology and pharmaceutical...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the European Medicines Agency (EMA) has requested that the Scientific Advisory Group on Oncology provide an opinion on the clinical...
Jim Cramer spotlights Under Armour, Tractor Supply, Enbridge, Casey's General Stores and Puma Biotechnology.
In markets like this, Jim Cramer says, tune out the noise and look at individual stocks like Disney, Boeing and Caterpillar.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology, Inc.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the European Patent Office has upheld the claims in Puma's licensed European patent (EP 2416774), which were being opposed by Hexal AG.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma's drug neratinib at the 2017 San Antonio Breast Cancer Symposium (SABCS) that...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Specialised Therapeutics Asia, an international biopharmaceutical company with strategic focus and expertise in Australia, New Zealand and South East...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the publication of previously presented results from the ExteNET Phase III clinical trial of Puma's drug neratinib in patients with early stage...
